Literature DB >> 3804901

Efficacy and safety of ciprofloxacin in patients with respiratory infections in comparison with amoxycillin.

I C Gleadhill, W P Ferguson, R C Lowry.   

Abstract

Ciprofloxacin and amoxycillin were compared in the treatment of respiratory infections (pneumonia, acute bronchitis, exacerbation of chronic lung disease) in a study of 48 patients randomly assigned to ten days treatment with standard doses of either drug. Forty-eight patients were evaluated, 26 in the ciprofloxacin group and 22 in the amoxycillin group. The response to therapy was judged by clinical and bacteriological criteria. Ciprofloxacin was as effective as amoxycillin with a successful outcome in 81% and 82% of cases respectively. A specific bacterial cause was determined in just over half the cases (28 patients) and eradication rates were higher for ciprofloxacin than for amoxycillin, 87% and 64% respectively. In particular, amoxycillin was unsuccessful in two patients infected with Branhamella catarrhalis. Both regimens were safe and produced little, if any, adverse effect (one possible episode in each treatment group). Ciprofloxacin was found to be as effective in bacterial respiratory tract infections as amoxycillin.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3804901     DOI: 10.1093/jac/18.supplement_d.133

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  13 in total

Review 1.  Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults.

Authors:  Noa Eliakim-Raz; Eyal Robenshtok; Daphna Shefet; Anat Gafter-Gvili; Liat Vidal; Mical Paul; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12

Review 2.  Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use.

Authors:  J H Paton; D S Reeves
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

Review 3.  Ciprofloxacin. A review of its pharmacological profile and therapeutic use in the elderly.

Authors:  L R Wiseman; J A Balfour
Journal:  Drugs Aging       Date:  1994-02       Impact factor: 3.923

Review 4.  Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia.

Authors:  J P Thys; F Jacobs; B Byl
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

Review 5.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

6.  Rufloxacin once daily in acute exacerbations of chronic bronchitis.

Authors:  M Dirksen; J Focht; J Boerema
Journal:  Infection       Date:  1991 Jul-Aug       Impact factor: 3.553

7.  Treatment of acute exacerbations of chronic bronchitis with ciprofloxacin.

Authors:  J A Hoogkamp-Korstanje; S J Klein
Journal:  Pharm Weekbl Sci       Date:  1987-12-11

8.  Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses.

Authors:  J T Lettieri; M C Rogge; L Kaiser; R M Echols; A H Heller
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

Review 9.  The use of oral fluoroquinolones in nursing home patients.

Authors:  T M File; J S Tan
Journal:  Drugs Aging       Date:  1992 Jul-Aug       Impact factor: 3.923

Review 10.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.